(Q37741787)

22 August 2017

1 reference

title

New pharmacological treatments for improving renal outcomes in diabetes (English)

1 reference

22 August 2017

1 reference

Anne-Emilie Declèves

1

1 reference

PubMed ID

20440278

22 August 2017

Kumar Sharma

series ordinal

2

1 reference

PubMed ID

20440278

22 August 2017

language of work or name

English

0 references

publication date

4 May 2010

1 reference

Nature Reviews Nephrology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

6

1 reference

22 August 2017

371-380

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.57

22 August 2017

0 references

cites work

Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Isoprenoids as mediators of the biological effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Racial Differences in the Progression from Chronic Renal Insufficiency to End-Stage Renal Disease in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Cellular and molecular mechanisms of proteinuria in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Epidemiology of microalbuminuria in diabetes and in the background population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The pathogenesis of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Angiotensin II compartmentalization within the kidney: effects of salt diet and blood pressure alterations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Angiotensin II induces superoxide anion production by mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Angiotensin II and renal fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

31 March 2020

NOX in liver fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renal and retinal effects of enalapril and losartan in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The RAAS in the pathogenesis and treatment of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Tissue activity of circulating prorenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

31 March 2020

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Structure-based design of aliskiren, a novel orally effective renin inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

First renin inhibitor, aliskiren, for the treatment of hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Aliskiren combined with losartan in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

LDL stimulates mesangial fibronectin production and chemoattractant expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Interstitial fibrosis in hypercholesterolemic rats: Role of oxidation, matrix synthesis, and proteolytic cascades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Statins for improving renal outcomes: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Study of Heart and Renal Protection (SHARP)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Mechanisms of tubulointerstitial fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Molecular basis of renal fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Interstitial fibrosis: tubular hypothesis versus glomerular hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Novel aspects of transforming growth factor-Beta in diabetic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

TGF-beta in diabetic kidney disease: role of novel signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

TGF-beta impairs renal autoregulation via generation of ROS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Soluble betaglycan reduces renal damage progression in db/db mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Simvastatin abates development of renal fibrosis in experimental renovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The treatment of liver fibrosis induced by hepatocyte growth factor-directed, ultrasound-targeted microbubble destruction in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pirfenidone improves renal function and fibrosis in the post-obstructed kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Pirfenidone is renoprotective in diabetic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

PAI-1 and kidney fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Protein kinase C activation and the development of diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

The effect of ruboxistaurin on nephropathy in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Genomic strategies for diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Application of proteomic analysis to the study of renal diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.57

Human prorenin: pathophysiology and clinical implications

31 March 2020

1 reference

12 December 2020

Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage

1 reference

12 December 2020

Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation.

1 reference

12 December 2020

Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio.

1 reference

12 December 2020

Angiotensin and cell growth: a link to cardiovascular hypertrophy?

1 reference

12 December 2020

Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat

1 reference

12 December 2020

Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations

1 reference

12 December 2020

Prevalence of chronic kidney disease and associated risk factors--United States, 1999-2004.

1 reference

12 December 2020

Potential role of TGF-beta in diabetic nephropathy

1 reference

12 December 2020

Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells

1 reference

12 December 2020

Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases

1 reference

12 December 2020

Epithelial to mesenchymal transition in the progression of tubulointerstitial fibrosis.

1 reference

12 December 2020

Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.57

1 reference

22 August 2017

1 reference

PubMed ID

20440278